Cormorant Asset Management’s Immuneering IMRX Stock Holding History

Cormorant Asset Management’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,295,273	Closed	-$9.52M	–	58
2024 Q1	$9.52M	Sell	3,295,273 -909,091	-22%	-$5.09M	0.42%	45
2023 Q4	$30.9M	Hold	4,204,364	–	–	1.48%	20
2023 Q3	$32.3M	Hold	4,204,364	–	–	1.88%	15
2023 Q2	$42.6M	Buy	4,204,364 +1,818,183	+76%	+$17.5M	2.39%	7
2023 Q1	$23.2M	Buy	2,386,181 +100,000	+4%	+$568K	1.53%	17
2022 Q4	$11.1M	Hold	2,286,181	–	–	0.74%	35
2022 Q3	$32.7M	Hold	2,286,181	–	–	2.29%	15
2022 Q2	$12.4M	Sell	2,286,181 -16,445	-0.7%	-$87.7K	0.94%	35
2022 Q1	$14.9M	Hold	2,302,626	–	–	1.14%	25
2021 Q4	$37.2M	Buy	2,302,626 +50,000	+2%	+$1.22M	2.21%	13
2021 Q3	$58.5M	Buy	+2,252,626	New	+$60.5M	2.38%	11

Other funds holding IMRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cormorant Asset Management's IMRX Position: Q2 2024 in Review

Cormorant Asset Management sold out of Immuneering (IMRX) in Q2 2024, closing a stake of 3,295,273 shares — an estimated $9.52M sold.

Cormorant Asset Management first reported a position in IMRX in Q3 2021 and held it in 11 quarters. The position peaked at $58.5M in Q3 2021. 59 funds tracked by Wall St. Rank hold IMRX as of Q2 2024.

Cormorant Asset Management reported no remaining Immuneering position as of Q2 2024 after selling out during the quarter.
Cormorant Asset Management sold 3,295,273 Immuneering shares in Q2 2024, an estimated $9.52M.
Cormorant Asset Management first reported a position in Immuneering in Q3 2021 and held it in 11 quarters.
Cormorant Asset Management's Immuneering position peaked at $58.5M in Q3 2021.
59 funds tracked by Wall St. Rank held Immuneering as of Q2 2024.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.